Videos

Dr. Sawsan Rashdan, an associate professor at UT Southwestern Medical Center specializing in lung cancer, discusses the transformative impact of targeted therapies and immunotherapies on NSCLC treatment.

Kerry Rogers, MD, provides a 7-year update on her study that evaluated the progression-free survival and factors associated with undetectable minimal residual disease status after treatment with a fixed-duration combination of obinutuzumab,...

In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, discuss the challenges and potential solutions for integrating cell and gene therapies—particularly CAR T—into clinical practice and insurance...

Federico Cappuzzo, MD, discusses the benefits of the subcutaneous formulation of atezolizumab compared with the intravenous route.

Mariana Gouveia, MD, gives an overview of the use of antibody-drug conjugates for the treatment of patients with endometrial cancer.

Abigail Zamorano, MD, MPHS, shares insights from a pilot study assessing a clinical algorithm, the the PREMM5 model, to evaluate a patient’s risk of carrying a Lynch Syndrome mutation, particularly in low-resource settings.

In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, talk about the economic challenges of precision medicine in health care, including the differences between Medicare and commercial health plans and...